Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)*

Organization & Developments: KalVista Pharmaceuticals

Parents

*KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors
2017: U.S. Biotech/Pharma Insights: A $1.3B Hedge Fund Invested $15M In This Harvard-Founded Company?_KalVista_seekingalpha
2020: KalVista Pharmaceuticals: Caution Warranted
2020: Trial flops see Pfizer cut GlycoMimetics pact, Merck ax KalVista research deal
2021: KalVista's rival to Takeda's Firazyr aces trial, sending stock up 200%
2023: KalVista's Sebetralstat: A Pill Worth Swallowing In HAE (NASDAQ:KALV)
2024: KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
2024: KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data
2024: KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
2024: KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement_seekingalpha.com
2024: KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
2024: KalVista: Upcoming PDUFA, But Not Without Risks